AVITA Medical Inc (ASX: AVH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AVITA Medical Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $205.59 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 153.16 million
Earnings per share -0.348
Dividend per share N/A
Year To Date Return 21.43%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AVITA Medical Inc (ASX: AVH)
    Latest News

    An excited man stretches his arms out above his head as he reaches a mountain peak.
    52-Week Highs

    7 ASX All Ordinaries shares smashing new 52-week highs today

    These shares are making investors very happy this Thursday.

    Read more »

    doctor with wide open mouth as if expressing surprise at rising avita share price
    Share Gainers

    Guess which ASX All Ordinaries stock has soared 50% in 3 days after reporting

    Here's why investors in this company have become a lot richer this week.

    Read more »

    A graphic image of three upward pointing arrows with smoke coming from their bottoms, indicating the arrows are taking off just like the Althea share price today
    Share Gainers

    3 ASX All Ordinaries shares that defied today's sell-off to leap higher

    We take a look at what's going on with these three ASX All Ordinaries shares.

    Read more »

    Happy healthcare workers in a labs
    Healthcare Shares

    Is there an $8 billion 'pot of gold at the end of the rainbow' for investors in this ASX healthcare share?

    It's been a rough few years for Avita shareholders.

    Read more »

    A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
    Ask a Fund Manager

    2 absolute bargain ASX shares to buy right now: analyst

    Ask A Fund Manager: Bell Direct's Grady Wulff examines three stocks that have plunged this year to see if they're…

    Read more »

    a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
    Share Gainers

    3 ASX All Ordinaries shares defying today's rout to surge higher

    These ASX All Ords shares are bucking today's sell-off.

    Read more »

    A sad looking scientist sitting and upset about a share price fall.
    Earnings Results

    Avita share price dives 16% on net loss

    The medical technology company's shares are falling following today's financial results

    Read more »

    medical asx share price represented by doctor giving thumbs up
    Share Gainers

    Why is the Avita Medical share price tracking 20% higher today?

    Shares in the regenerative medicine company continue their gains, tracking higher over the past month.

    Read more »

    Five healthcare workers standing together and smiling.
    Healthcare Shares

    Bell Potter names 2 of the best ASX healthcare shares to buy in FY23

    These healthcare shares could be buys for FY 2023...

    Read more »

    A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
    Earnings Results

    Avita Medical share price tumbles 7% on declining Q1 revenue

    The ASX healthcare share saw its net loss for the quarter increase 58% year-on-year.

    Read more »

    A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
    Healthcare Shares

    4 ASX healthcare shares at 52-week lows

    A number of ASX healthcare shares just hit 52-week lows.

    Read more »

    A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
    Small Cap Shares

    3 promising small cap ASX shares to watch

    Keep an eye on these small cap shares...

    Read more »

    Frequently Asked Questions

    No, AVITA Medical does not pay dividends at this time.

    AVITA Medical Inc listed on the ASX on 24 June 2020.

    Yes, as well as being listed on the ASX, AVITA Medical Inc is listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AVITA Medical Inc

    AVITA Medical Inc (ASX: AVH) is a healthcare company specialising in regenerative medicine. It is best known for its RECELL system, a burn treatment device that creates 'spray-on skin' from a patient's own skin cells within 30 minutes, avoiding or reducing the need for skin grafts.

    The product was originally invented and patented by Western Australian doctor and clinical professor Fiona Wood in 1993. 

    RECELL is approved for use in Australia, Europe, Canada, China, the Middle East, and Africa. It is also approved for treating adult patients in the US. As well as burns, AVITA Medical has evidence of RECELL's effectiveness for additional skin applications, such as treating chronic and traumatic wounds, scar revision, and vitiligo. 

    AVITA Medical Inc is domiciled and also listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    26 Feb 2026 $1.35 $-0.08 -5.59% 403,910 $1.38 $1.38 $1.33
    25 Feb 2026 $1.43 $0.13 9.96% 1,084,110 $1.45 $1.49 $1.40
    24 Feb 2026 $1.31 $0.03 2.35% 812,950 $1.35 $1.37 $1.30
    23 Feb 2026 $1.28 $0.08 6.69% 555,178 $1.28 $1.28 $1.25
    20 Feb 2026 $1.20 $-0.01 -0.83% 118,068 $1.20 $1.22 $1.20
    19 Feb 2026 $1.21 $0.02 1.68% 197,031 $1.21 $1.22 $1.19
    18 Feb 2026 $1.19 $0.00 0.00% 204,972 $1.19 $1.21 $1.19
    17 Feb 2026 $1.19 $-0.01 -0.83% 322,980 $1.20 $1.20 $1.14
    16 Feb 2026 $1.20 $0.12 11.11% 785,924 $1.19 $1.25 $1.19
    13 Feb 2026 $1.08 $-0.01 -0.92% 337,101 $1.10 $1.14 $1.08
    12 Feb 2026 $1.09 $-0.03 -2.68% 290,834 $1.11 $1.12 $1.08
    11 Feb 2026 $1.12 $0.00 0.00% 59,317 $1.13 $1.13 $1.12
    10 Feb 2026 $1.12 $0.01 0.90% 65,227 $1.13 $1.14 $1.12
    09 Feb 2026 $1.12 $0.02 1.83% 314,072 $1.13 $1.15 $1.12
    06 Feb 2026 $1.09 $-0.04 -3.52% 603,702 $1.13 $1.13 $1.08
    05 Feb 2026 $1.14 $-0.08 -6.58% 433,711 $1.21 $1.21 $1.14
    04 Feb 2026 $1.22 $0.00 0.00% 285,063 $1.23 $1.24 $1.21
    03 Feb 2026 $1.22 $-0.01 -0.81% 113,130 $1.22 $1.24 $1.21
    02 Feb 2026 $1.23 $0.00 0.00% 235,843 $1.26 $1.27 $1.22
    30 Jan 2026 $1.23 $-0.02 -1.60% 332,859 $1.22 $1.27 $1.21
    29 Jan 2026 $1.25 $-0.04 -3.10% 328,251 $1.30 $1.30 $1.24
    28 Jan 2026 $1.29 $-0.05 -3.73% 386,863 $1.31 $1.34 $1.28

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    22 Jan 2026 Suzanne Crowe Exercise 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Suzanne Crowe Buy 10,022 $11,675
    Conversion of securities. 22,990 CDIs, 42,336 Common Stock
    22 Jan 2026 Jeremy Curnock-Cook Buy 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Jeremy Curnock-Cook Exercise 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Jan Reed Buy 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Jan Reed Exercise 10,022 $11,675
    Conversion of securities. 2,891 RSUs
    22 Jan 2026 Cary Vance Exercise 10,022 $11,675
    Conversion of securities. 3,458 RSUs
    22 Jan 2026 Cary Vance Buy 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Robert McNamara Buy 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Robert McNamara Exercise 10,022 $11,675
    Conversion of securities. 3,458 RSUs
    16 Oct 2025 James Corbett Exercise 2,891 $4,712
    Conversion of securities. As per announcement
    16 Oct 2025 James Corbett Buy 2,891 $4,712
    Conversion of securities. As per announcement
    29 Aug 2025 Robert McNamara Buy 10,000 $45,000
    On-market trade. USD $
    20 Aug 2025 Robert McNamara Buy 10,000 $50,000
    On-market trade. USD $, As per announcement on 27-08-2025
    06 Jun 2025 Louis (Lou) Panaccio Exercise 9,200 $16,606
    Conversion of securities. 10,022 RSUs
    06 Jun 2025 Louis (Lou) Panaccio Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Suzanne Crowe Exercise 9,200 $16,606
    Conversion of securities. 10,022 RSUs
    06 Jun 2025 Suzanne Crowe Issued 9,200 $16,606
    Conversion of securities. 22,990 CDIs
    06 Jun 2025 Jeremy Curnock-Cook Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Jeremy Curnock-Cook Exercise 9,200 $16,606
    Conversion of securities. 10,022 RSUs
    06 Jun 2025 Jan Reed Exercise 9,200 $16,606
    Conversion of securities. 12,913 RSUs
    06 Jun 2025 Jan Reed Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Cary Vance Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Cary Vance Exercise 9,200 $16,606
    Conversion of securities. 16,938 RSUs
    06 Jun 2025 Robert McNamara Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Robert McNamara Exercise 9,200 $16,606
    Conversion of securities. 16,938 RSUs
    05 Jun 2025 Louis (Lou) Panaccio Issued 10,022 $18,340
    Issue of securities. 19,222 RSUs
    05 Jun 2025 Louis (Lou) Panaccio Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Suzanne Crowe Issued 10,022 $18,340
    Issue of securities. 19,222 RSUs
    05 Jun 2025 Suzanne Crowe Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Jeremy Curnock-Cook Issued 10,022 $18,340
    Issue of securities. 19,222 RSUs
    05 Jun 2025 Jeremy Curnock-Cook Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Jan Reed Issued 10,022 $18,340
    Issue of securities. 22,113 RSUs
    05 Jun 2025 Jan Reed Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 James Corbett Issued 520,000 $951,600
    Issue of options.
    05 Jun 2025 Cary Vance Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Cary Vance Issued 10,022 $18,340
    Issue of securities. 26,138 RSUs
    05 Jun 2025 Robert McNamara Issued 10,022 $18,340
    Issue of securities. 26,138 RSUs
    05 Jun 2025 Robert McNamara Issued 4,295 $7,859
    Issue of options.
    07 Mar 2025 Robert McNamara Buy 11,000 $91,300
    On-market trade. USD$

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Suzanne Crowe Non-Executive Director Jan 2016
    Ms Crowe is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. She is currently a Director of Sonic Healthcare Ltd, a large global medical diagnostics company. Past board positions include St. Vincent's Health Australia Ltd (2012-2021), the country's largest not-for-profit health and aged care provider. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and The Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her services to health, clinical governance, biomedical research, and education.
    Mr Jeremy Curnock-Cook Non-Executive Director Oct 2012
    Mr Cook is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Mr. Curnock Cook brings his international experience to our Board of Directors. Over his career, Mr. Curnock Cook has successfully managed more than US $1 billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. Mr. Curnock Cook founded a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. Mr. Curnock Cook has served on more than 40 boards of directors in the life science sector in the UK, Europe, USA, Canada, Japan and Australia.
    Ms Jan Stern Reed Non-Executive Director Jul 2021
    Ms Reed has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings expertise in corporate governance, compliance, and risk management. Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions.
    Mr Cary Vance Non-Executive DirectorNon-Executive ChairmanInterim CEO Apr 2023
    Mr Vance brings over 25 years of executive leadership experience across the global healthcare industry, with a in transformative medical technologies. He previously held CEO roles at PhotoniCare, Inc., Titan Medical, XCath, OptiScan Biomedical, Myoscience, and Hansen Medical. Earlier in his career, he held senior leadership positions at Teleflex, Covidien, and GE HealthCare. Mr Vance is Lean/Six Sigma Black Belt Certified.
    Mr Robert McNamara Non-Executive Director Apr 2023
    Mr McNamara is a senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His experience in operations and financial management spans across early stage, high growth, and mature companies. He is a former member of the Board of Directors and Chair of Audit Committee for Axonics, Inc. Additionally, Mr. McNamara is a member of the Board of Directors, Chair of the Compensation Committee, and member of the Audit Committee for Xtant Medical Holdings. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine. Prior to this role, he served as the Chief Financial Officer of three publicly traded medical device companies including Accuray, Somnus Medical Technologies, and Target Therapeutics.
    Dr Michael Eric Tarnoff Non-Executive Director Aug 2025
    Mr Tarnoff, spent 23 years at Tufts Medical Center in various executive roles, recently as Chief Physician Executive and CEO until 2024. He also served as Chief Medical Officer and Vice President, Medical Affairs at Medtronic from 2015 to 2019. From 2008 to 2015, he was corporate Chief Medical Officer and Vice President at Covidiens Surgical Devices division. His earlier roles include Medical Director at GI Dynamics (2006-2008) and Chief Medical Consultant at Tyco Healthcare (2005-2008).
    Mr Joseph(Joe) Fralin Woody Non-Executive Director Jan 2026
    Mr Woody is a healthcare executive with more than two decades of leadership experience across the medical technology sector, recently serving as CEO of Avanos Medical from 2017 to 2024, and previously, as President and CEO of Acelity Holdings. His background spans multiple senior executive roles, including with Covidien and Smith & Nephew. Across his storied professional career, Mr Woody also served on the Board of Directors of AdvaMed, Inc., the trade association in the U.S. for the medical device, diagnostics, and digital health technology sectors, for over a decade
    Mr Mark Andrew Licciardo Company Secretary Mar 2018
    -
    Ms Nicole Linda Kelsey Chief Legal and Compliance OfficerCompany Secretary Jul 2024
    -
    David O'Toole Chief Financial Officer
    -
    Nicole Linda Kelsey Chief Legal and Compliance OfficerCompany Secretary
    -
    Mark Andrew Licciardo Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Washington H Soul Pattinson And Company Limited 392,529 1.49%
    Citicorp Nominees Pty Limited 391,741 1.49%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 388,055 1.47%
    UBS Nominees Pty Ltd 345,782 1.31%
    Abn Amro Clearing Sydney Nominees Pty Ltd <Custodian A/C> 177,865 0.67%
    Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> 177,013 0.67%
    JP Morgan Nominees Australia Pty Limited 113,074 0.43%
    HSBC Custody Nominees (Australia) Limited 112,967 0.43%
    Taggart Investments Pty Ltd <Taggart Investment A/C> 86,000 0.33%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 76,729 0.29%
    Ioof Investment Services Limited <Ips Superfund A/C> 71,116 0.27%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 70,808 0.27%
    BNP Paribas Nominees Pty Ltd <Clearstream> 70,704 0.27%
    HSBC Custody Nominees (Australia) Limited i 65,237 0.25%
    HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> 61,465 0.23%
    Mr Andre Wall Ellis & Mrs Olivia Louise Ellis 60,000 0.23%
    Mrs Arlene Perry 60,000 0.23%
    Wairahi Investments Limited 60,000 0.23%
    Mr David Anthony Deelen 57,200 0.22%
    Dental Union Of Australia Pty Ltd <Ian Weatherlake S/F A/C> 56,000 0.21%

    Profile

    since

    Note